With Reva, Amaranth and Abbott out of the game, the pool of dissolving scaffold makers is shrinking.
The second half of 2019 saw half as many innovative medical devices approved as the first.
Robotic surgery is one of the bright spots in an otherwise tricky year for medtechs seeking a buyer.
2019’s medtech VC total is swollen by the sector’s first $1bn round, but counterintuitively the amount going to smaller groups is increasing.
New products and strategic execution buoyed mid and small-cap medtechs, while safety worries took down one former high-flier.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
Livongo Health, which launched a highly successful IPO in July, claims to be one of the fastest-growing companies in Silicon Valley. Can it keep investors happy as growth…